<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45338">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047526</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CIN-XXX-2012/1</org_study_id>
    <secondary_id>HF Registry-India</secondary_id>
    <nct_id>NCT02047526</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India</brief_title>
  <official_title>A Non-interventional, Prospective Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>India : Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional, prospective, multi-centric, cross-sectional study is aimed to
      observe clinical practice in India in managing Heart Failure patients &amp; to check one year
      outcome in HF patients. A total of 5 visits will be conducted during the study. There will
      be a baseline visit followed by four follow-up visits to assess the outcomes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-interventional, prospective study to evaluate the clinical epidemiology of patients
      with Heart Failure (HF) in India
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Cardiovascular hospitalization rates and Length of stay</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>HF related Hospitalization and hospital visits</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular and all cause mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Minnesota Living with Heart Failure Questionnaire scores.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with Dyspnea and/or signs of systemic congestion
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of subject informed consent

          2. Female or male aged 18 years and over

          3. All patients with Dyspnea and/or signs of systemic congestion

        Exclusion Criteria:

          1. Subjects with Current Acute Coronary Syndrome

          2. Absence of cardiac disease/structural heart disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ammar Raza, MBBS, DIP DIAB, MBA</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Pharma India Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R R Kasliwal, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medanta, The Medicity, Gurgaon</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
